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ObesityThe relationship between testosterone deﬁciency syndrome (TDS) and men's vascular health has a great impact
in the modern approach to the aging male. There is good evidence that low testosterone (T) is associated with
erectile dysfunction (ED) and that ED is a strongmarker for cardiovascular risk; also, TDS is frequently associated
with increased cardiovascular and all-causemortality. Noteworthy, the occurrence of increased levels of glucose,
total cholesterol, low-density lipoprotein, pro-inﬂammatory cytokines, andmyointimal carotid thicknessmay be
associatedwith reduced T levels especially in cardiac older frail men. Screening for low T should bemandatory in
high risk groups including those with type 2 diabetes, metabolic syndrome and obesity. The rising demand from
patients to be treated for ED associatedwith TDSwill increase the prescribing of T and facilitate future long-term
studies on its impact on cardiovascular disease (CVD). Recent studies suggestwarningswith regard to T prescrip-
tion in older frail men, but we regret that these studies had consistent bias in inclusion criteria and statistical
evaluation. Data from studies conducted in more selected populations suggest that T replacement therapy may
improve multiple surrogate markers for CVD as well as reducing cardiovascular mortality. After analyzing the
most important studies' limitation, we can conclude that at present there is insufﬁcient evidence of a causal
relationship between T therapy and adverse cardiovascular outcomes to support against T supplementation in
older hypogonadal frail men.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).The European Male Aging Study (EMAS) stated that the 3 cardinal
symptoms most likely to be related to low testosterone (T) levels are:
i. erectile dysfunction-ED, ii. reduced sexual desire and iii. loss of
morning erections [1]. Guidelines suggest that a level of a total-T of
b8 nmol/L (231 ng/dL) or free-T of less than 180 pmol/L (52 pg/mL)
require T replacement therapy (TRT) and total-T of N12 nmol/L
(346 ng/dL) or free-T of N225 pmol/L (64.8 pg/mL) do not [2]. Between
these levels a trial of therapy should be considered based on major
symptoms' presence. Less speciﬁc symptoms include hot ﬂushes,
sweats, tiredness, loss of vitality, reduced shaving frequency, gyneco-
mastia, depressed mood and poor concentration, and sleep distur-
bances. Furthermore, EMAS reported a prevalence of TDS at 5.1% in a
non-obese male population of 70–79, whereas studies on populations
with Type 2 diabetes report TDS prevalence rates of 40% and of
15–30% in men presenting with ED. Accordingly, the presence of
hypogonadism in men with CVD is about two times higher than
observed in the general population and is associated with an increaseDept. Experimental Medicine,
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land Ltd. This is an open access articlof the most known cardiovascular risk factors, and cardiovascular
morbidity and mortality [3]. The most recent studies have also
identiﬁed that men with CVD show signiﬁcantly lower serum levels of
bioavailable T than those men with negative coronary angiography.
Recent studies appeared in prestigious international journals rose
the concern regarding TRT in elderly hypogonadal frail men. The ﬁrst
study was conducted by Basaria et al. [4] and evaluated the efﬁcacy of
T-gel in approximately 200 elderly men at high risk for cardiovascular
disease (CVD). The study was discontinued due to an overall imbalance
of various cardiovascular-related adverse events. Four occurrences of
major adverse cardiac events (MACE) were reported in the T-group
and none in the placebo group; the two groups were not balanced for
cardiovascular risk (CVR) factors, which could explain the imbalance
in MACE and prevented a meaningful interpretation of drug causality.
Also, only elderly men with a high-risk of CVD and low-normal T levels
were enrolled, with the intention to restore normal serumT.We strong-
ly believe that this population is not representative of the true
hypogonadal men as the deﬁnition given in EMAS study, that makes
unclear whether these patients were replaced or supplemented with
T. The very popular study by Vigen et al. [5] was a retrospective cohort
study aimed to investigate the association between T therapy and
all-cause CVD mortality in men with TDS (b300 ng/dL) who had
undergone coronary angiography between the years 2005 and 2011.e under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Time course (the ‘clock’) of testosterone effects on the cardiovascular system (from ref [6], modiﬁed).
2 A. Aversa et al. / IJC Metabolic & Endocrine 4 (2014) 1–3The study reported two corrections since its original publication as well
as a series of analytical errors in data, so that 29 companies and more
than 160 medical experts in the ﬁeld have claimed to the Editor for its
retraction. Also, a numerical error occurred for over 1000 subjects
in one group, and over 900 subjects in a second group, and surprisingly,
almost 10% of the male population was composed of women.
Noteworthy, men had baseline average T level of 175.5 ng/dL and
post-treatment level of 332.2 ng/dL, which, despite within the normal
range, is below the treat-to-target range recommended for
T-substitution (400–500 ng/dL) [6]. In our experience, this range
maybe as higher as 450–550 ng/dL in particular population i.e. obese/
metabolic syndrome/diabetic patients (Fig. 1). Last but not least, the
exclusion of 128 patients who experienced myocardial infarction (MI)
or stroke before initiating T treatment appeared inappropriate. These
patients should have been included in the analysis and their events
included in the no-T group, which would have raised the event rate in
the no-T group by 71%. Their exclusion biased the results by reducing
the number of events in the no-T group, as we and other international
experts have already outlined [7]. The meta-analysis by Xu et al. [8]
assessed the risk of cardiovascular events in 2994 men who received
T-therapy or placebo for at least 12 weeks during 1986–2012. The trial
just included every sort of T-therapy independently of drug formulation
and dose, without caring the exposure to treatment, ranging from some
weeks to some years; baseline characteristics, such as class of CVR
factor, comorbidities and baseline T-levels of the patients were not
stratiﬁed. The authors deﬁned the primary safety outcome as “compos-
ite cardiovascular-related events” instead of MACE, thus anticipating
too few events for a robust assessment by cardiovascular event
type. They also noted a discrepancy in T-associated risk between
industry-funded andnon-funded trials. Butﬁve out of the fourteen trials
not funded by industry reported usingmedication given by pharmaceu-
tical companies and eight of the non-industry funded trials either did
not provide dear information on funding source or described industry
consultancies or other industry ties. Finkle et al. [9] conducted a
retrospective cohort study to assess a possible association between
T-therapy and non-fatal MI 90 days following an initial prescription by
using a large MarketScan administrative database. However, in these
data, the diagnostic indications for T treatment were not available. In
addition, results of laboratory testing of T-levels were not available;
this might have been very important, as low serum T is a known riskfor cardiovascular events. T exposure was determined based on
patient's ﬁlling of a prescription for T-therapy, but it is unknown
whether the patient had really used the prescription. This fact,
combinedwith the inability to assess baseline or post-treatment plasma
T levels or, indication for therapy associatedwith themales treatedwith
T, makes it impossible to determine if the treat-to-target T levels were
attained. Due to these limitations, it is difﬁcult to completely attribute
the increased risk for non-fatal MI to T treatment. Also, it is unclear if
3-months' follow-up is adequate to capture relevant outcomes.
Basic science supports the facts that T increases the mRNA
expression of the androgen receptor on endothelial cells, inducing an
inhibition of the formation of neo-intimal plaques and that it induces
rapid vasodilation, suggesting a non-genomic effect of T on vascular
system. In humans, it is now established that T is inversely correlated
with the severity of atherosclerosis and carotid intima–media thickness,
both early predictors of cardiac mortality; its administration have
beneﬁcial effects on vascular reactivity, inﬂammation, cytokines proﬁle,
molecular adhesion, insulin-resistance, lipid proﬁle and surrogate
markers of atherosclerosis [10]. Furthermore, chronic TRT improves
anginal symptoms to cardiac stress test [11] and represents a promising
in the treatment of heart failure associated with TDS [12].
We herein provide evidence supporting the acute and chronic
beneﬁcial effects of TRT in men with CVD, (Fig. 1) mainly due to
improvements of abdominal obesity and to its anti-atherogenic and
endothelium-protective effects. We suggest that the condition of
comorbid TDS associated with CVD will be properly managed and
treated long-term by strictly monitoring treat-to-target T levels in
selected older frail men. TRT withdrawal in these subjects returns
back to CVR burden before treatment, suggesting that this maybe a
lifelong treatment unless contraindicated.
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